Background
==========

The last decade has witnessed a tremendous progress in understanding the molecular pathology and the pathogenesis of colorectal carcinoma (CRC). Chromosomal as well as microsatellite instability and the CpG island methylator phenotype have been defined as major molecular pathogenetic mechanisms, giving rise to the main molecular classes of CRC \[[@B1],[@B2]\]; and genome wide mutational analysis have shown that per individual cancer a limited number of signal transduction pathways are dysregulated by \"driver\" mutations in some (typically about 15) from a set of about 80 so-called candidate cancer genes \[[@B3],[@B4]\].

In the wake of this, targeted therapies for CRC are beginning to enter the clinics, EGF-receptor blockade (with the pre-requisite of K-Ras mutational analysis) being the first already to be used more generally among these \[[@B5],[@B6]\]. It may be expected for the near future that patient\'s tumor tissues, besides being subject to traditional histopathological examination, will be used for various additional molecular testings. While some of these can be done with conventional paraffin-embedded material, some will require frozen tumor tissue. But, conceivably, more elaborate molecular analyses or even functional tests eventually may be desirable, and for these analyses at least xenograft tumors may be prime choice \[[@B7]-[@B9]\].

However, xenografting as a routine will pose considerable logistical difficulties as technical expertise of different fields (surgery, pathology, molecular biology and animal care) must be brought together. Clearly, separating location and occasion when the tumor specimen accrues, the molecular analyses are done, and the engraftings are performed would rigorously reduce this logistical complexity. In addition, at least for research purposes, it would allow preselection of tumor specimens with desired molecular features in advance of the technically demanding xenografting procedures.

We here report an easy and effective method to store CRC tissue by cryopreservation for use in xenografting at a later date. Specifically, we aimed to explore feasibility and success rate in a consecutive series of CRCs collected ad hoc, comparing xenografting of tumor tissue fresh from surgery with xenografting after cryopreservation. In addition, we demonstrate that cryopreservation of established xenograft tumors for re-xenografting is also feasible. And finally, we show that a balanced distribution of the different molecular classes of CRCs will be obtained.

Methods
=======

Tumor specimen collection and cryopreservation
----------------------------------------------

Resection specimens of primary tumors (N = 48; primary CRCs without previous chemo-or radiotherapy) were received fresh from surgery. Tumor tissue cubes (ca. 3 × 3 × 3 mm) were cut from the deep invasive parts with a sterile scalpel blade.

Mirror blocks for cryostat sections were prepared from the adjacent parts of the tumours. Alternatively, xenograft tumors were removed under sterile conditions and pieces were taken from the peripheral parts of the tumors. Again, adjacent tumour tissues were used for cryostat sections. Typically, 4 tumor pieces were transferred into sterile cryo-tubes (greiner-bio-one, Frickenhausen, Germany) in 1.5 ml freezing medium (foetal calf serum containing 10% DMSO), sealed in a Freezing Container (Nalgene, Rochester, NY, USA), and placed immediately at -80°C. Until transplantation tubes were kept at -80°C (for a maximum of 6 weeks) or, after overnight cooling, transferred into liquid nitrogen (for longer storage periods). For xenografting, cryopreserved tumor pieces were thawed at 37°C. Prior informed consent was obtained in written from all patients, and all procedures were approved by the Ethics Committee of the University of Rostock (reference number II HV 43/2004) in accordance with generally accepted guidelines for the use of human material.

Tumor xenografting
------------------

Tumor xenograftings were done by one of the following approaches: (I) xenografting of primaries on the day of surgery (n = 23); (II) xenografting of primaries after cryopreservation (n = 31); and (III) re-transplantation of xenografts after cryopreservation (n = 11). Tumor pieces were implanted subcutaneously uni-or bilaterally into the flanks of six to eight week old female mice under ether anaesthesia for a short period of time. We used NOD-SCID (NOD.CB17-Prkdcscid/J in cases of HROC24 to HROC46 and nude mice (NMRI nu/nu) for the subsequent xenograftings. As assessed by cryostat sections from the mirror blocks, there was seen an area fraction of 30 - 80% of viable tumour in the tissues used for xenografting. The numbers of mice receiving grafts and the numbers of grafts for each animal are given for each individual tumor in Table [1](#T1){ref-type="table"}. Mice were kept in the animal facilities of the medical faculty of the University of Rostock and maintained in specified pathogen-free conditions. Animals were exposed to 12-h light/12-h darkness cycles and standard food and water including antibiotics (Co-trimoxazol) ad libitum. Their care and housing were in accordance with guidelines as put forth by the German Ethical Committee and the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Research Council; NIH Guide, vol.25, no.28, 1996). Growth of tumours to volumes of 1 - 1.5 cm^3^was taken as evidence of successful xenografting, and the animals were then sacrificed for collection of tumour tissues for further studies.

###### 

Details of xenograftings and outcomes.

  Tumor-ID   Fresh                 Cryopreserved                       Days frozen
  ---------- --------------------- ----------------------------------- -------------
  HROC24     M1(+); M2(-); M3\*                                        
                                                                       
  HROC26     M1(-); M2(-); M3(-)                                       
                                                                       
  HROC29     M1(+); M2(+); M3(-)                                       
                                                                       
  HROC32     M2(+); M1\*                                               
                                                                       
  HROC33     M1(-); M2(-); M3(-)                                       
                                                                       
  HROC37     M1(-); M2(-)                                              
                                                                       
  HROC38     M1(-); M2(-)                                              
                                                                       
  HROC39     M1(+); M2(+)                                              
                                                                       
  HROC40     M1(+); M2(+)                                              
                                                                       
  HROC45     M1(-); M2(-)                                              
                                                                       
  HROC46     M1(+); M2(+)                                              
                                                                       
  HROC48                           M1(-;-); M2(-;-);M3(+;+); M4(+;-)   161/643
                                                                       
  HROC50                           M1(+;+); M2(-;+)                    120
                                                                       
  HROC51                           M1(-;-); M2(-;-)                    117
                                                                       
  HROC52                           M1(-;-); M2(-;-)                    94
                                                                       
  HROC53                           M1(-;+); M2(-;-)                    84
                                                                       
  HROC54                           M1(-;-); M2(-;+)                    64
                                                                       
  HROC55                           M1(-;-); M2(-;-);M3(-;+); M4(-;-)   6/489
                                                                       
  HROC56     M1(-); M2(-)                                              
                                                                       
  HROC57     M1(+); M2(-)                                              
                                                                       
  HROC59     M1(+;+); M2(-;+)                                          
                                                                       
  HROC60     M1(-;+); M2(-;-)                                          
                                                                       
  HROC61                           M1(-;-); M2(-;-)                    58
                                                                       
  HROC62                           M1(-;-); M2(+;-)                    51
                                                                       
  HROC63     M1(-;+); M2(-;-)      M1(-;-); M2(-;-)                    88
                                                                       
  HROC64                           M1(+;-); M2(-;-)                    78
                                                                       
  HROC65     M1(+;-); M2(-;-)      M1(+;-); M2(-;-)                    13
                                                                       
  HROC66                           M1(-;-); M2(-;-)                    47
                                                                       
  HROC67                           M1(-;-); M2(-;-)                    42
                                                                       
  HROC68     M1(+;+); M2(+;+)      M1(-;+); M2(-;+)                    38
                                                                       
  HROC69     M1(+;+); M2(+;+)      M1(-;-); M2(-;-)                    28
                                                                       
  HROC70     M1(-;-); M2(-;+)      M1(-;+); M2(-;-)                    27
                                                                       
  HROC71                           M1(+;+); M2(-;+)                    27
                                                                       
  HROC72                           M1(+;+); M2(-;-)                    240
                                                                       
  HORC73                           M1(-;-); M2(-;-)                    238
                                                                       
  HROC74                           M1(+;+); M2(-;-)                    230
                                                                       
  HROC75                           M1(-;+); M2(+;+)                    223
                                                                       
  HROC78                           M1(+;+); M2(-;-)                    188
                                                                       
  HROC80                           M1(-;+); M2(-;-)                    119
                                                                       
  HROC81                           M1(-;-); M2(-;+)                    118
                                                                       
  HROC82                           M1(+;+); M2(-;-)                    118
                                                                       
  HROC83                           M1(-;-); M2(-;-)                    87
                                                                       
  HROC84                           M1(-;+); M2(-;-)                    73
                                                                       
  HROC85     M1(-;+); M2(+;+)                                          
                                                                       
  HROC86     M1(-;+)                                                   
                                                                       
  HROC87                           M1(-;+); M2(-;+)                    9
                                                                       
  HROC88                           M1(+;+); M2(-;+)                    7
                                                                       
  HROC89     M1(-;-); M2(+;-)      M1(+;+)                             103

M denotes mice xenografted, the outcome is given in parentheses as index + or index -. One index is given for uni-and two indices for bilateral xenografts. \* animals died due to problems with anaesthesia. Underlined: repetition of the xenografting procedure.

Morphological and molecular studies
-----------------------------------

Dissections and histopathological examination of the primary tumors were done according to standard protocols for surgical pathology reports of CRCs \[[@B10]\], and additional staging information was compiled from patients\' clinical charts. Primary tumors and xenografts were embedded in paraffin, and 4 μm H&E sections were obtained as well as β-catenin and MLH1 and MSH2 immunostainings.

The molecular analyses were done as previously published in detail \[[@B2]\]. Briefly, the Bethesda panel of microsatellite markers was used to test for microsatellite instability, chromosomal instability was assessed by DNA-flow cytometry and LOH analyses with various dinucleotide markers (D5S1385, D5S346 (5q21); D8S1734, D8S1771, NEFL (8p21); D9S942, D9S1748 (9p21); D17S1832, D17S250 (17p23); D18S70 (18q23)), and mutation analyses of the APC gene as well as the K-Ras and B-Raf genes were done. Finally, DNA-methylation was assessed by the MethyLight technology with the marker panel originally published by Ogino et al. and modified by us \[[@B2]\]. Based on these molecular data, tumors in this series were classified as sporadic standard type CRC (spStdCRC), sporadic high-degree microsatellite instable CRC (spMSI-H), hereditary non-polyposis CRC-type (HNPCC-type), or CpG island methylator phenotype CRC (CIMP-type).

Verification of human origin of the xenograft tumors
----------------------------------------------------

A human specific PCR was performed by amplification of a portion of the human mitochondrial cytochrome b gene as previously described \[[@B11]\]. Briefly, the reaction mixture (25 μl) contained 25 ng of gDNA, 0.1 mM of each primer (L15674: TAGCAATAATCCCCATCCTCCATATAT, H15782: ACTTGTCCAATGATGGTAAAAGG), 200 μM dNTPs, 1 × standard reaction buffer and 0.1 U Taq DNA polymerase (Bioron, Ludwigshafen, Germany). PCR was performed in a standard thermal cycler for 40 cycles of 30 s at 96°C, 40 s at 59°C, and 1 min at 72°C. Products were separated on a 1% agarose gel and results were scored positive with the appearance of a band of 157 bp.

Statistics
----------

All data were entered into a computerized data bank (Statistical Package for the Social Sciences, SPSS version 13.0). Testing for significance of cross-tabulated data was done by two-sided Fisher\'s exact T-test. The criterion for significance was taken to be p \< 0.05.

Results
=======

Overall, 48 primary CRCs were collected for these xenografting experiments. 47 were adenocarcinomas, and 1 tumor was a large cell neuroendocrine carcinoma (HROC 57). Information on histological and molecular types as well as staging information and patient characteristics are summarized in Table [2](#T2){ref-type="table"}.

###### 

Data of colorectal carcinomas used for xenografting experiments and overall results of outcomes.

  Tumor-ID   Age/Gender   Site\*        TNM-Stage   Molecular type^†^   Fresh     Cryo
  ---------- ------------ ------------- ----------- ------------------- --------- ---------
  HROC24     98/m         Right colon   G2T2N0M0    spMSI               Success   ND^‡^
                                                                                  
  HROC26     60/m         Left colon    G3T4N2M1    spStd               Failure   ND
                                                                                  
  HROC29     59/m         Right colon   G3T3N2M1    HNPCC               Success   ND
                                                                                  
  HROC32     82/f         Right colon   G2T4N2M1    spStd               Success   ND
                                                                                  
  HROC33     70/f         Left colon    G2T3N1M0    spStd               Failure   ND
                                                                                  
  HROC37     77/m         Right colon   G3T2N0M0    ND                  Failure   ND
                                                                                  
  HROC38     67/f         Right colon   G2T3N0M0    spStd               Failure   ND
                                                                                  
  HROC39     69/m         Right colon   G3T4N0M0    spStd               Success   ND
                                                                                  
  HROC40     69/m         Left colon    G3T3N1M0    CIMP-H              Success   ND
                                                                                  
  HROC45     52/m         Right colon   G3T4N0M0    ND                  Failure   ND
                                                                                  
  HROC46     66/m         Right colon   G3T3N0M1    spStd               Success   ND
                                                                                  
  HROC48     68/m         Right colon   G3T2N1M0    spMSI               ND        Success
                                                                                  
  HROC50     67/f         Right colon   G2T4N0M0    spMSI               ND        Success
                                                                                  
  HROC51     70/m         Left colon    G3T4N2M1    spStd               ND        Failure
                                                                                  
  HROC52     55/f         Left colon    G2T2N0M0    spStd               ND        Failure
                                                                                  
  HROC53     72/f         Right colon   G3T3N0M0    spMSI               ND        Success
                                                                                  
  HROC54     63/f         Left colon    G2T3N2M0    spStd               ND        Success
                                                                                  
  HROC55     81/f         Right colon   G3T2N0M0    spMSI               ND        Success
                                                                                  
  HROC56     70/m         Right colon   G1T3N0M0    ND                  Failure   ND
                                                                                  
  HROC57     43/m         Right colon   G3T3N2M1    NA^§^               Success   ND
                                                                                  
  HROC59     76/m         Right colon   G2T3N1M1    spStd               Success   ND
                                                                                  
  HROC60     71/m         Right colon   G2T2N0M0    CIMP-H              Success   ND
                                                                                  
  HROC61     57/m         Rektum        G3T3N0M0    spStd               ND        Failure
                                                                                  
  HROC62     84/f         Right colon   G3T4N2M0    spStd               ND        Success
                                                                                  
  HROC63     81/f         Left colon    G2T4N0M0    spStd               Success   Failure
                                                                                  
  HROC64     71/m         Left colon    G2T2N0M0    spStd               ND        Success
                                                                                  
  HROC65     73/f         Right colon   G3T3N2M1    spStd               Success   Success
                                                                                  
  HROC66     75/m         Rektum        G2T3N2M0    spStd               ND        Failure
                                                                                  
  HROC67     54/m         Left colon    G2T3N1M0    spStd               ND        Failure
                                                                                  
  HROC68     84/m         Left colon    G2T4N2M0    spStd               Success   Success
                                                                                  
  HROC69     62/m         Right colon   G3T3N0M1    spStd               Success   Failure
                                                                                  
  HROC70     65/f         Right colon   G3T4N1M0    spStd               Success   Success
                                                                                  
  HROC71     52/m         Right colon   G2T3N0M0    HNPCC               ND        Success
                                                                                  
  HROC72     61/m         Right colon   G2T3N2M1                        ND        Success
                                                                                  
  HORC73     69/m         Left colon    G2T3N0M0                        ND        Failure
                                                                                  
  HROC74     80/m         Left colon    G2T4N0M0    spStd               ND        Success
                                                                                  
  HROC75     58/m         Left colon    G2T3N0M0    spStd               ND        Success
                                                                                  
  HROC78     75/m         Right colon   G3T3N0M0    CIMP-H              ND        Success
                                                                                  
  HROC80     72/m         Right colon   G2T3N2M1                        ND        Success
                                                                                  
  HROC81     21/f         Right colon   G3T4N0M1    spStd               ND        Success
                                                                                  
  HROC82     62/m         Right colon   G2T3N0M0                        ND        Success
                                                                                  
  HROC83     85/f         Right colon   G2T3N1M1                        ND        Failure
                                                                                  
  HROC84     88/f         Left colon    G2T3N0M0    spStd               ND        Success
                                                                                  
  HROC85     65/m         Rektum        G2T3N0M0    spStd               Success   ND
                                                                                  
  HROC86     79/f         Left colon    G2T3N1M0    spStd               Success   ND
                                                                                  
  HROC87     76/f         Left colon    G3T3N0M0    spMSI               ND        Success
                                                                                  
  HROC88     69/f         Right colon   G2T3N1M0                        ND        Success
                                                                                  
  HROC89     80/m         Rektum        G2T3N0M1    spStd               Success   Success

\* Right colon (coecum to splenic flexure), left colon (descending colon and sigmoid), Rektum. † Abbreviations for molecular types of colorectal carcinomas. ‡ ND - not determined/not done. § NA - not applicable.

Xenografting of 23 tumors fresh from surgery was successful in 17 cases (74% take). By comparison, 31 tumors were xenografted after cryopreservation for 6 to 643 days, and this was successful in 22 cases (71% take - summarized in Table [2](#T2){ref-type="table"}), Thus, there was not observed a statistically significant difference in the overall success rates between fresh (n = 17/23) and cryopreserved (n = 22/31) samples (p = 0.815, Fisher\'s exact T-test). As most animals received bilateral xenografts comparison between total numbers of fresh and cryopreserved xenografts could be made. Again, the difference was not statistically significant although a trend to reduced success after cryopreservation was observed (n = 34/68; 50% fresh, n = 40/130; 31% cryopreserved, p = 0,098; Table [1](#T1){ref-type="table"}). In two cases, where xenografts did not grow successfully after cryopreservation, enough frozen tumor pieces were left to repeat xenografting at a much later date (643 and 489 days), this time with success (animals M3 and M4 of HROC48 and HROC55; Table [1](#T1){ref-type="table"}, underlined).

For 6 of the 48 tumors, sufficient material was available to attempt both xenografting of tumor tissue fresh from surgery and xenografting of tumor tissues after cryopreservation (13 to 103 days). This was successful for all the tumor tissues xenografted fresh from surgery, and for 4 cases of cryopreserved tissues (67%; Table [2](#T2){ref-type="table"}). Details on the xenograftings and their outcomes are given in Table [1](#T1){ref-type="table"}.

Re-transplantation of xenograft tumors after cryopreservation was attempted for 11 tumors, and this could be carried out successfully in all cases. These tumor tissues were from passages 2 to 8 and had been cryopreserved for 56 to 455 days (Table [3](#T3){ref-type="table"}). In terms of grafts, 47 of 54 grafts were accepted (87%; Table [3](#T3){ref-type="table"}).

###### 

Successful re-xenografting after cryopreservation.

  Tumor-ID   Passage number   Days frozen     Success rate by grafts
  ---------- ---------------- --------------- ------------------------
  HROC24     3                148             2/2
                                              
  HROC29     6-8              147, 182, 189   7/10
                                              
  HROC32     5                168             4/4
                                              
  HROC39     2                164             4/4
                                              
  HROC40     2                191             4/4
                                              
  HROC46     2                455             7/8
                                              
  HROC50     2, 3             120, 168        5/6
                                              
  HROC53     2, 3             84, 168         6/6
                                              
  HROC54     2                56              2/2
                                              
  HROC59     2                119             2/2
                                              
  HROC71     2                141             4/4

As expected, histologically the xenograft tumors closely resembled their primaries (Figure [1](#F1){ref-type="fig"}). PCR studies amplifying part of the human mitochondrial cytochrome b gene gave further proof of the human origin of these tumors (data not shown). Furthermore, the molecular analyses revealed that xenografting could be carried out successfully for all the molecular types of CRC without any evident bias. Specifically, xenografts were obtained for 27 spStdCRC, 6 spMSI-H tumors, 2 HNPCC-type tumors, and 3 CIMP tumors.

![**Tumor morphology**. Examples of (a) primary tumor (HROC50) and (b) its xenograft. Compared to its primary, the tumor architecture, growth pattern, and cytological features are well preserved in the xenograft tumor.](1471-2407-10-362-1){#F1}

Generally, xenografting was well tolerated by the animals. No signs of superinfection or suppuration were seen in any of the cases and consequently, no death from infection occurred. This was even true for those cases where tumor samples contained bacteria as judged from infections observed in parallel cultures in vitro (data not shown). In this series, we never observed metastases.

Discussion
==========

In this study, we were able to show that tumor tissue from primary CRC surgical resection specimens can be cryopreserved and successfully xenografted into mice even after prolonged periods of storage (up to 643 days). Even though take rates with this procedure seem to be lower than with tumor tissue used fresh from surgery (71% overall take for cryopreserved vs. 74% overall take for fresh tissues), this difference was not of statistical significance. Besides, it is still satisfactory and compares favourably to xenograft take rates reported by other groups \[[@B12]-[@B15]\]. Not unlikely, take rates could even be improved by increasing the number of implantations or by Matrigel-soaking of tumor pieces before xenografting as suggested by Fujii et al. as well as by Sorio et al. \[[@B14],[@B15]\]. The latter group was also the first to report a successful cryopreservation technique for pancreatic cancers \[[@B14]\]. As a technically very simple method, cryopreservation of CRC tumor tissue prior to xenografting as reported here may be quite appealing to both clinical and basic researchers alike for the following reasons:

\(1\) Cryopreservation before xenografting considerably reduces logistic constraints. If tumor tissue is xenografted fresh from surgery the work-flow is very complex. At first liaison will have to be made with the surgical colleagues for the resection specimen to be brought to the pathology department. From there the tumor tissue is handed over to the xenograft-team, often past usual work-hours; and presuming in any case that there are animals ready for use in the breeding-facilities on the day of surgery. Obviously, putting a break into this will make the procedure much easier.

\(2\) Cryopreservation before xenografting facilitates collection of large numbers of tumor specimens, even from different centres. This may be important for pre-clinical studies addressing e.g. the effects of targeted therapies as it has been shown that human tumor xenografts can be used for prediction, especially when panels are used \[[@B16],[@B7]-[@B9]\]. Conceivably, even, cryopreservation could allow post hoc analysis and propagation in xenografts of those patients\' tumor tissue that have responded (or not responded) to specific therapies.

\(3\) Cryopreservation before xenografting allows preselection of frozen tumor samples out of a larger collection. This drastically reduces time and resources needed to obtain individual xenografts of a desired molecular type. Important to note in this respect is, apparantly by our procedure none of the major molecular types of CRC would be excluded.

\(4\) Finally, we observed that cryopreservation of established xenografts of CRC samples for later re-transplantation is particularly successful (100% take in terms of cases and 87% in terms of grafts). This may be interesting if low-passage xenografts are desired, as it has been shown that similar to cell lines xenografts may acquire additional mutations and changes in the karyotype \[[@B17],[@B12]\]; and it is very convenient in relieving laboratories from the necessity of continuous passaging. Moreover, it will greatly facilitate the exchange of well-characterized models between different institutions.

Conclusions
===========

In the presented study we demonstrate the feasibility of xenografting of clinical CRC specimens after a transient cryopreservation step. A statistical comparison of the success rates with and without cryopreservation revealed no significant difference. In addition, we show that cryopreservation of established xenograft tumors for re-xenografting is particularly feasible. And finally, we show that a balanced distribution of the different molecular classes of colorectal carcinomas will be obtained using this procedure. These findings may have immediate impact on the improvement of preclinical drug testing procedures. To the best of our knowledge; this has never been done for CRC.
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